Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that women with female pattern hair loss experienced improvements in hair loss severity and quality of life from low-dose oral minoxidil use, despite a common side effect of unwanted hair growth, which most did not consider a reason to stop treatment.

In this prospective study, individuals with androgenetic alopecia using a home-use low-level laser therapy helmet for 48 weeks experienced significant increases in hair density and thickness, with reported improvements consistent across sexes and no device-related adverse events.

This study suggests that low-dose oral minoxidil is safe and effective in treating COVID-19 associated telogen effluvium, as indicated by a significant decrease in hair-shedding scores over follow-up visits.

In this study, researchers observed that approximately 1.15% of dengue fever patients experienced alopecia, predominantly among females. The hair loss usually occurred during the recovery phase and was often identified as telogen effluvium, with lower platelet count and hematocrit levels potentially serving as risk factors.

This review highlights the potential benefits of low-level light therapy for treating various alopecias, with reported improvements in hair density and count, especially when combined with minoxidil or finasteride, but it offers no new clinical results.

In this study, low-intensity ultrasound was investigated as a noninvasive method for promoting hair regrowth in androgenetic alopecia using C57BL/6 male mice, revealing that specific frequencies and intensities can safely enhance hair regrowth compared to controls by optimizing mechanical effects without causing unsafe cavitation.

In this retrospective study, researchers reported that low-dose oral minoxidil significantly improved hair density in 60 patients with androgenetic alopecia or telogen effluvium over 4-8 months, as detected through standardized AI-powered imaging.

This study's network meta-analysis reported that botulinum injection combined with red laser and topical minoxidil is most effective for increasing hair density in androgenetic alopecia when using low-level laser therapy.

In this report, two pediatric patients with short anagen syndrome, a condition causing difficulty in growing long scalp hair, showed positive responses to low‐dose oral minoxidil treatment.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

This study found that low-dose oral minoxidil (≤5 mg/day) effectively increased hair number and diameter in men and women with androgenetic alopecia, and was generally well-tolerated with mostly mild adverse effects, although serious complications were rare and associated mainly with pre-existing heart conditions.

Low-dose oral minoxidil does not significantly affect blood pressure in patients with hair loss and hypertension.

Low-dose oral minoxidil may be a promising alternative to topical minoxidil for hair loss.

In this study, low concentrations of DMSO were found to decrease androgen receptor expression and inhibit the migration of prostate cancer cells, suggesting potential as an anticancer therapy.

This review highlights that while low-dose oral minoxidil appears well-tolerated in cancer patients post-chemotherapy, its use during active chemotherapy has shown potential benefits but remains under investigation, with preclinical studies suggesting a protective effect against chemotherapy-induced alopecia.

In this study, the combination of low-level laser therapy and topical minoxidil was found to improve hair density and diameter more effectively than minoxidil alone in treating androgenic alopecia, with similar safety profiles observed in both groups.

Spironolactone is safe for treating hair loss in women without causing low blood pressure.

Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.

In this study, the researchers found that tyndallization effectively sterilizes aqueous solutions of hyaluronic acid without diminishing their regenerative properties, and these properties remain intact even at low temperatures, supporting potential applications in cryobiology and cryomedicine.

This study highlights the diverse prescribing and monitoring practices for low-dose oral minoxidil among dermatologists in the UK and Ireland, used widely for various hair loss conditions both as monotherapy and adjunctive therapy.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

Results are not provided in this abstract. It discusses a comparison between the efficacy of minoxidil alone and in combination with low-level laser therapy for treating androgenic alopecia.

This article discusses the rising use of low-dose oral minoxidil for androgenetic alopecia and mentions common side effects like hypertrichosis, but provides no new clinical findings.

This study reports the draft genome sequence of the endangered Indus River dolphin and suggests potential genetic adaptations to freshwater environments, including specialized skin features and immune adaptations, while also highlighting historical and human-induced factors contributing to its low genetic diversity.

This retrospective study in a tertiary hair clinic concluded that routine monitoring of heart rate, weight, liver, and kidney function is not necessary for asymptomatic patients with normal baseline values undergoing low-dose oral minoxidil treatment, although monitoring is advised for those with preexisting renal impairment.

In this study, injectable microdepots containing rapamycin and poly(lactic-co-glycolic acid) were developed and demonstrated to effectively promote hair regrowth in mice by sustaining drug release and inducing anagen phase transition in hair follicles through modulating autophagy and the Wnt/β-catenin pathway.

This study found that a combination of microneedling with growth factors and low-level light therapy led to visible hair regrowth without side effects in a patient with trichotillomania.

Low-dose oral minoxidil doesn't affect blood pressure in patients taking blood pressure meds.

This study found that microspicule cosmetics with low-molecular-weight peptide complexes significantly improved skin whitening, pore condition, and skin barrier function over four weeks compared to a non-microspicule formulation.

This study reviewed adverse events associated with low-dose oral minoxidil for treating alopecia, finding hypertrichosis and fluid retention as common, typically manageable side effects without needing treatment discontinuation.